ROSEN, REGARDED INVESTOR RIGHTS COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious safety concerns, including device malfunctions causing dangerously high insulin dosing and hypoglycemic events, with thousands of complaints filed. The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.